Policy statement on antimicrobial stewardship by the society for healthcare epidemiology of america (SHEA), the infectious diseases society of america (IDSA), and the pediatric infectious diseases society (PIDS)

Infection Control and Hospital Epidemiology

Volumn 33, Issue 4, 2012, Pages 322-327

  Fishman, Neil ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

ACCURACY; AMBULATORY CARE; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; DRUG COST; EDUCATION; HEALTH CARE ORGANIZATION; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HEALTH PROGRAM; HOSPITALIZATION; HUMAN; INTENSIVE CARE; OUTCOME ASSESSMENT; PATIENT SAFETY; PUBLIC HEALTH; RESPONSIBILITY; TRANSLATIONAL RESEARCH; UNITED STATES;

AMBULATORY CARE; ANTI-INFECTIVE AGENTS; BIOMEDICAL RESEARCH; DRUG RESISTANCE, MICROBIAL; DRUG UTILIZATION REVIEW; HUMANS; ORGANIZATIONAL POLICY; PROGRAM EVALUATION; SOCIETIES, MEDICAL; UNITED STATES;

EID: 84858802951     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/665010     Document Type: Article

References (37)

1. Penicillin finder assays its future. New York Times. 26 June 1945: 21.
2. Spink WW, Ferris V. Quantitative action of penicillin inhibitor from penicillin-resistant strain of Staphylococcus. Science 1945; 102:221-223.
3. Barrett FF, McGehee RF, Finland M. Methicillin-resistant Staphylococcus aureus at Boston City Hospital. N Engl J Med 1968; 279:441-448.
4. Centers for Disease Control and Prevention NNIS System. National Nosocomial Infections Surveillance (NNIS) systemreport, data summary from January 1992-April 2000; issued June 2000. Am J Infect Control 2000;28:429-448.
5. Herold BC, Immergluck LC, Maranan MC, et al. Communityacquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 1998;279:593-598.
6. Naimi TS, LeDell KH, Como-Sabetti K, et al. Comparison of community-and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003;290:2976-2984.
7. Deleo FR, Otto M, Kreisworth BN, Chambers HF. Communityassociated meticillin-resistant Staphylococcus aureus. Lancet 2010;375:1557-1568.
8. Lynch JP 3rd, Zhanel GG. Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines. Curr Opin Pulm Med 2010;16:217-225.
9. Deguchi T, Nakane K, Yasuda M, Maeda S. Emergence and spread of drug resistant Neisseria gonorrhoeae. J Urol 2010;184: 851-858.
10. Parry CM, Threlfall EJ. Antimicrobial resistance in typhoidal and nontyphoidal salmonellae. Curr Opin Infect Dis 2008;21: 531-538.
11. Jacobson KR, Tierney DB, Jeon CY, Mitnick CD, Murray MB. Treatment outcomes among patients with extensively drugresistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2010;51:6-14.
12. Bonten MJ, Willems R, Weinstein RA. Vancomycin-resistant enterococci: why are they here, and where do they come from? Lancet Infect Dis 2001;1:314-325.
13. Chavers LS, Moser SA, Benjamin WH, et al. Vancomycinresistant enterococci: 15 years and counting. J Hosp Infect 2003; 53:159-171.
14. Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis 2001;1:147-155.
15. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 2009;9:228-236.
16. Ho J, Tambyah PA, Paterson DL. Multiresistant gram-negative infections: a global perspective. Curr Opin Infect Dis 2010;23: 546-553.
17. Oteo J, Pérez-Vázquez M, Campos J. Extended-spectrum betalactamase producing Escherichia coli: changing epidemiology and clinical impact. Curr Opin Infect Dis 2010;23:320-326.
18. Garnacho-Montero J, Amaya-Villar R. Multiresistant Acinetobacter baumannii infections: epidemiology and management. Curr Opin Infect Dis 2010;23:332-339.
19. Zavascki AP, Carvalhaes CG, Picão RC, Gales AC. Multidrugresistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy. Expert Rev Anti Infect Ther 2010;8:71-93.
20. Falagas ME, Rafailidis PI, Matthaiou DK, Virtzili S, Nikita D, Michalopoulos A. Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: characteristics and outcome in a series of 28 patients. Int J Antimicrob Agents 2008;32:450-454.
21. Chen LF, Chopra T, Kaye KS. Pathogens resistant to antibacterial agents. Infect Dis Clin N Am 2009;23:817-845.
22. Rice LB. The clinical consequences of antimicrobial resistance. Curr Opin Microbiol 2009;12:476-481.
23. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! an update from the Infectious Diseases Society of America. Clin Infect Dis 2009;48:1-12.
24. Lautenbach E, Weiner MG, Nachamkin I, Bilker WB, Sheridan A, Fishman NO. Imipenem resistance among Pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes. Infect Control Hosp Epidemiol 2006;27:893-900.
25. Roberts RR, Hota B, Ahmad I, et al. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin Infect Dis 2009;49:1175-1184.
26. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008;29:1099-1106.
27. Filice GA, Nyman JA, Lexau C, et al. Excess costs and utilization associated with methicillin resistance for patients with Staphylococcus aureus infection. Infect Control Hosp Epidemiol 2010;31: 365-373.
28. Mauldin PD, Salgado CD, Hansen IS, Durup DT, Bosso JA. Attributable hospital cost and length of stay associated with health care-associated infections caused by antibiotic-resistant gram-negative bacteria. Antimicrob Agents Chemother 2010;54: 109-115.
29. Infectious Diseases Society of America. The 10 # 20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis 2010;50:1081-1083.
30. Infectious Diseases Society of America. Antimicrobial resistance. http://www.idsociety.org/AR_Policy/. Accessed October 27, 2010.
31. Shlaes DM, Gerding DN, John JF Jr, et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Infect Control Hosp Epidemiol 1997;18: 275-291.
32. Shlaes DM, Gerding DN, John JF Jr, et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 1997;25:584-599.
33. Dellit TH, Owens RC, McGowan JE Jr, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007;44: 159-177.
34. Spellberg B, Blaser M, Guidos RJ, et al. For the Infectious Diseases Society of America. Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis 2011;52(suppl 5): S397-S428.
35. Department of Health and Human Services. HHS action plan to prevent healthcare-associated infections. http://www.hhs.gov/ ash/initiatives/hai/actionplan/index.html. Accessed October 27, 2010.
36. Gilbert DN, Spellberg B, Bartlett JG for the Infectious Diseases Society of America. Position paper: an unmet medical need: rapid molecular diagnostic tests for respiratory tract infections. Clin Infect Dis 2011;52(suppl 4):S384-S395.
37. Gilbert DN. Use of plasma procalcitonin levels as an adjunct to clinical microbiology. J Clin Microbiol 2010;48:2325-2329.